Mission Therapeutics Receives £1.9M Grant from Innovate UK

Mission Therapeutics, a Cambridge, UK-based drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer and other diseases, received a £1.9m grant from Innovate UK.

The company will use the funds for the discovery of preclinical DUB inhibitors directed at specific deubiquitylating enzymes (DUBs). DUBs are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs.

Led by Anker Lundemose, Chief Executive Officer, Mission Therapeutics will use its proprietary technology platform to identify novel chemical entities targeting a particular DUB that lies at a key node of oncogenic signaling. Ultimately, these inhibitors will be used for treating malignancies with high unmet need for the benefit of cancer sufferers worldwide.

Founded in 2011, the company has received £27 million in venture capital from a blue chip syndicate comprising institutional (Sofinnova Partners, Imperial Innovations) and corporate (SR One, Roche Venture Fund and Pfizer) investors and is based at the Babraham Research Campus, south of Cambridge.

FinSMEs

25/09/2015

Join the discussion